Home

VHCP Management III, LLC

CIK 1738053 · last filed 2024-02-01

VHCP Management III, LLC is a corporate insider who has filed 14 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing shows the insider bought $8.9M of KALV on Feb 1, 2024. Across all open-market trades the lifetime net is +$345.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $15.4M across reported positions. The firm reports its address in New York, NY. 57 SEC filings were submitted jointly with Nimish P Shah.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$15.39M

Companies

5

Total Filings

14

Lifetime Open-Market Net

$345.16M

Filer Profile

Reported Address
7 BRYANT PARK
23RD FLOOR
NEW YORK, NY 10018
Phone
(650) 561-9580
State of Incorporation
DE
Related Filers
Nimish P Shah — 57 joint filings, latest 2026-03-27
VHCP Co-Investment Holdings III, LLC — 57 joint filings, latest 2026-03-27
Bong Y Koh — 52 joint filings, latest 2026-03-27
VHCP Management EG, LLC — 42 joint filings, latest 2026-03-27
Venrock Healthcare Capital Partners EG, L.P. — 42 joint filings, latest 2026-03-27
VHCP Co-Investment Holdings II, LLC — 33 joint filings, latest 2022-10-26
Venrock Healthcare Capital Partners II, L.P. — 33 joint filings, latest 2022-10-26
ASSOCIATES IV L P VENROCK — 5 joint filings, latest 2019-10-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KalVista Pharmaceuticals, Inc. (KALV) Delisted 10%+ Owner 4,738,683 $27.00 $127.94M $11.26M 2 2024-02-01
Tricida, Inc. (TCDA) Delisted 10%+ Owner 8,088,998 $0.11 $873.6K $43.29M 6 2022-10-26
ALT 10%+ Owner 4,500,000 $3.42 $15.39M $181.64M 2 2020-06-15
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted 10%+ Owner 4,016,873 $33.99 $136.53M $110.40M 1 2019-12-16
Bellerophon Therapeutics, Inc. (BLPH) Delisted 10%+ Owner 429,012 $0.01 $5.1K -$1.43M 3 2019-10-28

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-02-01 KalVista Pharmaceuticals, Inc. (KALV) Delisted Buy (P) +616,693 $8.92M EDGAR
2024-01-16 KalVista Pharmaceuticals, Inc. (KALV) Delisted Buy (P) +183,722 $2.34M EDGAR
2022-10-26 Tricida, Inc. (TCDA) Delisted Sell (S) −64,515,400 -$35.02M EDGAR
2022-10-03 Tricida, Inc. (TCDA) Delisted Buy (P) +4,369,230 $46.97M EDGAR
2022-07-25 Tricida, Inc. (TCDA) Delisted Buy (P) +741,990 $6.87M EDGAR
2022-07-20 Tricida, Inc. (TCDA) Delisted Buy (P) +1,500,000 $13.77M EDGAR
2022-06-21 Tricida, Inc. (TCDA) Delisted Buy (P) +59,510 $576.7K EDGAR
2022-06-14 Tricida, Inc. (TCDA) Delisted Buy (P) +1,180,540 $10.11M EDGAR
2020-06-15 ALT Buy (P) +12,000,000 $90.48M EDGAR
2020-05-28 ALT Buy (P) +10,429,088 $91.16M EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.